RASSF1A promoter methylation is associated with increased risk of thyroid cancer: A meta-analysis

OncoTargets and Therapy

Volumn 10, Issue , 2017, Pages 247-257

  Shou, Feiyan ^a   Xu, Feng ^a   Li, Gang ^a   Zhao, Zhenhua ^a   Mao, Ying ^a   Yang, Fangfang ^a   Wang, Hongming ^a   Guo, Hangyuan ^a  

^a SHAOXING PEOPLE S HOSPITAL   (China)

Author keywords

Meta analysis; Methylation; RASSF1A; Thyroid neoplasms

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ARTICLE; ASIAN; CANCER RISK; CANCER STAGING; CAUCASIAN; CONTROLLED STUDY; DISTANT METASTASIS; DNA METHYLATION; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; POLYMERASE CHAIN REACTION; PROMOTER REGION; RASSF1A GENE; RISK ASSESSMENT; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

EID: 85009516254     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S124417     Document Type: Article

References (47)

1. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.
2. Brito JP, Davies L. Is there really an increased incidence of thyroid cancer? Curr Opin Endocrinol Diabetes Obes. 2014;21(5):405–408.
3. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev. 2009;18(3):784–791.
4. Morris LG, Myssiorek D. Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg. 2010;200(4):454–461.
5. Elisei R, Pinchera A. Advances in the follow-up of differentiated or medullary thyroid cancer. Nat Rev Endocrinol. 2012;8(8):466–475.
6. Fagin JA, Wells SJ. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(11):1054–1067.
7. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88(5):1139–1148.
8. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the surveillance, epidemiology and end results (SEER) program 1973–1991. Cancer. 1997;79(3):564–573.
9. Raue F, Kotzerke J, Reinwein D, et al. Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German medullary thyroid carcinoma register. Clin Investig. 1993;71(1):7–12.
10. Roos L, van Dongen J, Bell CG, et al. Integrative DNA methylome analysis of pan-cancer biomarkers in cancer discordant monozygotic twin-pairs. Clin Epigenetics. 2016;8:7.
11. Kartal K, Onder S, Kosemehmetoglu K, Kilickap S, Tezel YG, Kaynaroglu V. Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material. BMC Cancer. 2015;15:824.
12. Ellis RJ, Wang Y, Stevenson HS, et al. Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype. J Clin Endocrinol Metab. 2014;99(2):E329–E337.
13. Allen NP, Donninger H, Vos MD, et al. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene. 2007;26(42):6203–6211.
14. Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers. 2007;23(1–2):73–87.
15. Guo C, Tommasi S, Liu L, Yee JK, Dammann R, Pfeifer GP. RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr Biol. 2007;17(8):700–705.
16. van der Weyden L, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta. 2007;1776(1):58–85.
17. Yu GS, Lai CY, Xu Y, Bu CF, Su ZX. Aberrant methylation of RASSF1A gene contribute to the risk of renal cell carcinoma: a meta-analysis. Asian Pac J Cancer Prev. 2015;16(11):4665–4669.
18. Huang YZ, Wu W, Wu K, Xu XN, Tang WR. Association of RASSF1A promoter methylation with lung cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(23):10325–10328.
19. Jiang D, Shen Y, Dai D, et al. Meta-analyses of methylation markers for prostate cancer. Tumour Biol. 2014;35(10):10449–10455.
20. Si JG, Su YY, Han YH, Chen RH. Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: a meta-analysis. Genet Test Mol Biomarkers. 2014;18(6):394–402.
21. Ashktorab H, Rahi H, Wansley D, et al. Toward a comprehensive and systematic methylome signature in colorectal cancers. Epigenetics. 2013;8(8):807–815.
22. Li YS, Xie Q, Yang DY, Zheng Y. Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies. Mol Biol Rep. 2014;41(6):3925–3933.
23. Shi DT, Han M, Gao N, Tian W, Chen W. Association of RASSF1A promoter methylation with gastric cancer risk: a meta-analysis. Tumour Biol. 2014;35(2):943–948.
24. Jiang Y, Cui L, Chen WD, Shen SH, Ding LD. The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data. PLoS One. 2012;7(5):e36780.
25. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19(4):251–253.
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
27. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
28. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–748.
29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
30. Santoro A, Pannone G, Carosi MA, et al. BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy. J Cell Biochem. 2013;114(5):1174–1182.
31. Brait M, Loyo M, Rosenbaum E, et al. Correlation between BRAF mutation and promoter methylation of TIMP3, RARbeta2 and RASSF1A in thyroid cancer. Epigenetics. 2012;7(7):710–719.
32. Mohammadi-asl J, Larijani B, Khorgami Z, et al. Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARbeta2 genes in papillary thyroid carcinoma. Med Oncol. 2011;28(4):1123–1128.
33. Lee JJ, Geli J, Larsson C, et al. Gene-specific promoter hypermethylation without global hypomethylation in follicular thyroid cancer. Int J Oncol. 2008;33(4):861–869.
34. Nakamura N, Carney JA, Jin L, et al. RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest. 2005;85(9):1065–1075.
35. Xing M, Cohen Y, Mambo E, et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res. 2004;64(5):1664–1668.
36. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res. 2002;62(13):3698–3701.
37. Qu F, Xue WJ. RASSF1A methylation and its clinical roles in papillary thyroid carcinoma. J Nantong University (Medical Sciences). 2012;32:490–491.
38. Dai YL, Cai DH, Chen H, Zhang Z, Zhang H, Li J. The association of the methylation of TSHR and RASSF1A with thyroid cancer. Shaanxi Med J. 2011;4011:1446–1449.
39. Wang XH, Zhang GC, Liu YL, Sun GF, Nong WX, Yao ES. The detection of RASSF1A promoter methylation in thyroid tumor patients. Shaanxi Med J. 2009;38:790–792.
40. Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2002;87(4):1814–1818.
41. Elisei R, Shiohara M, Koeffler HP, Fagin JA. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer. 1998;83(10):2185–2193.
42. Khaled H, Al Lahloubi N, Rashad N. A review on thyroid cancer during pregnancy: multitasking is required. J Adv Res. 2016;7(4):565–570.
43. St BR, Zheng L, Liu W, Winer D, Asa SL, Ezzat S. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology. 2005;146(3):1145–1153.
44. Kondo T, Zheng L, Liu W, Kurebayashi J, Asa SL, Ezzat S. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res. 2007;67(11):5461–5470.
45. Jiang JL, Tian GL, Chen SJ, Xu LI, Wang HQ. Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: a meta-analysis. Exp Ther Med. 2015;10(4):1549–1555.
46. Qu F, Xue WJ. RASSF1A methylation and its clinical roles in papillary thyroid carcinoma. J Nantong University (Medical Sciences). 2012;32: 490–491.
47. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res. 2002;62(13): 3698–3701.